Krystal Biotech, Inc. Share Price
KRYSKrystal Biotech, Inc. Stock Performance
Open $309.45 | Prev. Close $309.18 | Circuit Range N/A |
Day Range $309.45 - $319.71 | Year Range $127.99 - $319.71 | Volume 12,431 |
Average Traded $313.36 |
Krystal Biotech, Inc. Share Price Chart
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
10-Jun-26 | $309.45 | $312.39 | +0.00% |
10-Jun-26 | $309.45 | $312.39 | +0.90% |
09-Jun-26 | $309.41 | $309.62 | +2.56% |
08-Jun-26 | $303.00 | $301.90 | +0.45% |
05-Jun-26 | $308.23 | $300.56 | -2.42% |
04-Jun-26 | $300.01 | $308.00 | +2.05% |
03-Jun-26 | $290.95 | $301.81 | +3.03% |